USFDA Concludes Inspection at Zydus' USA Office with Nil Observations
Zydus Lifesciences Ltd 路 Press Release 路 26 Sept 2026, 5:57 pm
USFDA Concludes Inspection at Zydus' USA Office with Nil Observations The USFDA conducted an on-site inspection of the pharmacovigilance and post-marketing surveillance systems at Zydus Lifesciences Limited's office located in New Jersey, USA. The regulatory audit took place from 22nd Sep'26 to 25th Sep'26 and concluded successfully with nil observations, reaffirming regulatory compliance for the company's US operations.
Original exchange filing (PDF)
More announcements from Zydus Lifesciences Ltd
- Press Release 路 14 Nov 2026
- Completion of transaction 路 12 Nov 2026
- Transcript of the post results earnings call held on November 4, 2026. 路 07 Nov 2026
- Press Release 路 07 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India 路 06 Nov 2026
- Investor Conference 路 06 Nov 2026
- Audio recording of the Company's Investor Call 路 05 Nov 2026
- Press Release 路 04 Nov 2026
